Ancora Heart Receives IDE Approval for CorCinch-HF Pivotal Study of the AccuCinch® Ventricular Restoration System

Ancora Heart Enrolls First Patient in The CORCINCH-HF Study

Ancora Heart, Inc., a company developing a novel therapy to address heart failure, today announced enrollment of the first patient in the CORCINCH-HF pivotal trial.

Ancora Heart Secures $80 Million in Financing

Ancora Heart Appoints Mark Miles as Chief Commercial Officer

Ancora Heart Receives Breakthrough Device Designation from FDA for the AccuCinch® Ventricular Restoration System

ANCORA HEART’S ACCUCINCH SYSTEM DEMONSTRATES SIGNIFICANT IMPROVEMENT IN QUALITY OF LIFE, CARDIAC STRUCTURE AND FUNCTION IN HEART FAILURE PATIENTS

Ancora Heart Inc. and egnite, Inc. Announce Strategic Partnership to Accelerate Clinical Trial Enrollment for Heart Failure Patients

To Learn More

GET IN TOUCH